<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antimicrobial therapy of left-sided native valve endocarditis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antimicrobial therapy of left-sided native valve endocarditis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antimicrobial therapy of left-sided native valve endocarditis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vivian H Chu, MD, MHS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to the antimicrobial therapy of native valve infective endocarditis (IE) will be reviewed here; the content reflects American, British, and European guidelines [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         An overview of the management of IE in adults is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults"
         </a>
         .)
        </p>
        <p>
         General issues related to echocardiography are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5323.html" rel="external">
          "Role of echocardiography in infective endocarditis"
         </a>
         .)
        </p>
        <p>
         Issues related to clinical manifestations and diagnosis of native valve endocarditis, complications of IE, and indications for surgery are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">
          "Complications and outcome of infective endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">
          "Surgery for left-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p>
         Issues related to right-sided IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2149.html" rel="external">
          "Right-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p>
         Issues related to management of prosthetic valve IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">
          "Surgery for prosthetic valve endocarditis"
         </a>
         .)
        </p>
        <p>
         Issues related to management of cardiac device infections are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116021.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         Issues related to management of mycotic aneurysm and brain abscess are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">
          "Overview of infected (mycotic) arterial aneurysm"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">
          "Treatment and prognosis of bacterial brain abscess"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bactericidal agents are necessary for effective treatment of endocarditis. Therefore, antimicrobial therapy should be dosed to optimize sustained bactericidal serum concentrations throughout as much of the dosing interval as possible. In vitro determination of the minimum inhibitory concentration should be performed routinely.
        </p>
        <p>
         Early consultation with a cardiac surgeon should be obtained for cases in which complications are observed or expected (such as in infections complicated by moderate to severe heart failure). In addition, consultation by specialists in infectious diseases and cardiology may be very useful.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, therapy for infective endocarditis (IE) should be targeted to the organism isolated from blood cultures; cultures are positive in over 90 percent of patients with IE. For patients with suspected IE who present without acute symptoms, empiric therapy is not always necessary, and therapy can await blood culture results. Results of blood cultures are usually available within one to three days, and an accurate diagnosis is a critical first step in designing a management strategy. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         In some cases, a clinician may choose to initiate antibiotic therapy prior to blood culture results; the decision to start or withhold antibiotic therapy prior to a microbiologic diagnosis must be individualized. For example, we initiate empiric antibiotic therapy for patients with hemodynamic instability and clinical presentation suggestive of acute endocarditis (eg, fever and new murmur, particularly in the setting of relevant cardiac risk factors [such as prior IE, history of valvular or congenital heart disease] or other predisposing conditions [intravenous drug use, indwelling intravenous lines, immunosuppression, or a recent surgical procedure]). Empiric therapy should be administered after at least two (preferably three) sets of blood cultures have been obtained from separate venipunctures and ideally spaced over 30 to 60 minutes. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
         The choice of empiric therapy should take into consideration the most likely pathogens. In general, empiric therapy should cover staphylococci (methicillin susceptible and resistant), streptococci, and enterococci.
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 1
         </a>
         ) is an appropriate choice for initial therapy in most patients. Additional issues related to the approach to empiric treatment of
         <em>
          Staphylococcus aureus
         </em>
         bacteremia are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Empiric antibiotic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Clinical response to initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with IE become afebrile three to five days after initiation of appropriate antimicrobial therapy. Patients with
         <em>
          S. aureus
         </em>
         endocarditis may respond somewhat more slowly, remaining febrile for five to seven days after initiation of therapy. Patients with right-sided endocarditis and septic pulmonary emboli may remain febrile for an even longer duration of time.
        </p>
        <p>
         The initial microbiologic response to therapy should be assessed by obtaining repeat blood cultures 48 hours after antibiotics are begun; it is reasonable to obtain at least two sets of blood cultures every 24 to 48 hours until bloodstream infection has cleared [
         <a href="#rid1">
          1
         </a>
         ]. Thereafter, careful serial physical examinations should be performed to evaluate for signs of heart failure, emboli, or other complications. Patients who develop new complications while on appropriate antimicrobial therapy (such as new emboli, heart failure, heart block, or other complications) should have a repeat echocardiogram to assess for worsening valve dysfunction, cardiac abscess, or fistula.
        </p>
        <p class="headingAnchor" id="H100587039">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy depends on the site of valvular infection and on the specific pathogen, as discussed in the sections below and as summarized in the tables (see
         <a class="local">
          'Specific pathogens'
         </a>
         below). The duration of therapy should be counted from the first day of negative blood cultures (for cases in which blood cultures were initially positive) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         In general, the suggested duration of therapy in patients with native valve endocarditis (NVE) ranges up to six weeks (with the exception of NVE due to highly resistant enterococcus, for which the duration is at least six weeks). Some data suggest that a shortened duration of intravenous therapy may be sufficient in some cases [
         <a href="#rid4">
          4,5
         </a>
         ]; however, thus far, the weight of this evidence has been insufficient to change practice. A full course of therapy is particularly important for patients with virulent or relatively resistant pathogens, secondary cardiac or extracardiac complications, and in the setting of prolonged infection prior to diagnosis.
        </p>
        <p>
         This approach is based upon our understanding of the pathogenesis of vegetation formation and pathogen susceptibility, rather than on an evidence-based approach based on outcome data. Prolonged therapy is presumed to be necessary because bacterial concentrations within vegetations are as high as 10
         <sup>
          9
         </sup>
         to 10
         <sup>
          11
         </sup>
         colony-forming units/gram of tissue; in addition, organisms within vegetations are not accessible to phagocytic cells and may be in a state of reduced metabolic activity [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2140.html" rel="external">
          "Pathogenesis of vegetation formation in infective endocarditis"
         </a>
         .)
        </p>
        <p>
         Shorter regimens may be reasonable in selected patients. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with right-sided endocarditis (see
         <a class="medical medical_review" href="/z/d/html/2149.html" rel="external">
          "Right-sided native valve infective endocarditis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with endocarditis due to susceptible viridans streptococci [
         <a href="#rid7">
          7
         </a>
         ] (see
         <a class="local">
          'Viridans streptococci and S. bovis/S. equinus complex'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with endocarditis due to HACEK organisms (see
         <a class="local">
          'HACEK organisms'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         A shortened duration of parenteral therapy has been studied in select patients with left-sided endocarditis. In one study (Partial Oral Treatment of Endocarditis, or POET trial), including 400 Danish patients with NVE due to methicillin-susceptible
         <em>
          S. aureus
         </em>
         (23 percent), streptococci (54 percent),
         <em>
          Enterococcus faecalis
         </em>
         (25 percent), or coagulase-negative staphylococci (13 percent) who completed at least 10 days of intravenous therapy, patients in stable condition were randomly assigned to continue intravenous treatment or switch to oral treatment with a two-drug antibiotic regimen; the groups completed a similar duration of therapy (median 19 versus 17 days, respectively) [
         <a href="#rid4">
          4
         </a>
         ]. Treatment completion with oral antibiotic therapy was noninferior to continued intravenous antibiotic therapy; the primary outcome (a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen [from the time of randomization until six months after completion of therapy]) occurred in 12 versus 9 percent of patients (between-group difference 3.1 percentage points, 95% CI 3.4-9.6).
        </p>
        <p>
         In subsequent follow-up of patients in the POET trial [
         <a href="#rid5">
          5,8
         </a>
         ], the primary composite outcome at five years occurred less frequently among those who completed oral treatment (32.8 versus 45.2 percent; hazard ratio 0.65, 95% CI 0.47-0.90). While these are encouraging findings, the results are difficult to generalize given a number of factors including microbial etiology (streptococci were the most common pathogen among study participants; methicillin-resistant
         <em>
          S. aureus
         </em>
         was relatively uncommon among study participants), high rate of surgical therapy; selection bias (only 20 percent of assessed patients were randomly assigned), and referral bias (all patients received care in tertiary centers). Therefore, we have not altered our treatment approach based on these data; further study of oral antibiotic therapy for completing treatment of IE is needed.
        </p>
        <p class="headingAnchor" id="H4111444479">
         <span class="h2">
          Completing therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may complete intravenous therapy as outpatients once hemodynamically stable. They must be capable of managing the technical aspects of intravenous therapy. Such patients require careful monitoring and must have ready access to full medical care should complications occur [
         <a href="#rid1">
          1,9
         </a>
         ]. Patients should be counseled regarding the need for immediate evaluation in the setting of new fever, chills, or other signs of systemic toxicity, including a thorough clinical evaluation and repeat blood cultures [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117307.html" rel="external">
          "Outpatient parenteral antimicrobial therapy"
         </a>
         .)
        </p>
        <p>
         While on antimicrobial therapy, patients should be monitored for antimicrobial toxicity. Weekly laboratory monitoring (complete blood count, chemistries, liver function tests) should be performed. Serial audiograms may be appropriate for patients receiving long-term aminoglycosides [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Issues related to echocardiographic monitoring during therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults", section on 'Echo monitoring during therapy'
         </a>
         .)
        </p>
        <p>
         Patients should be monitored for development of complications related to IE, including embolic complications and heart failure (see
         <a class="medical medical_review" href="/z/d/html/2142.html" rel="external">
          "Complications and outcome of infective endocarditis"
         </a>
         ). Development of complications should prompt evaluation for cardiac surgery. (See
         <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">
          "Surgery for left-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18272320">
         <span class="h2">
          Follow up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to follow up after completion of antibiotic therapy for IE are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/118215.html" rel="external">
          "Overview of management of infective endocarditis in adults", section on 'Follow-up'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3116614268">
         <span class="h2">
          Relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with relapse of NVE following completion of appropriate antimicrobial therapy should receive a repeat course of antibiotics as described in the following sections.
        </p>
        <p>
         Bacterial isolates should be retested carefully for complete antibiotic susceptibility profiles.
        </p>
        <p class="headingAnchor" id="H3697026328">
         <span class="h1">
          SPECIFIC PATHOGENS
         </span>
        </p>
        <p class="headingAnchor" id="H1412510770">
         <span class="h2">
          Staphylococci
         </span>
         <span class="headingEndMark">
          —
         </span>
         The success of therapy for staphylococcal endocarditis depends on a number of factors, including involvement of right- versus left-sided valvular structures and the susceptibility of the staphylococcal isolate.
        </p>
        <p>
         Occasional strains of
         <em>
          S. aureus
         </em>
         are penicillin susceptible; however, laboratory screening procedures for detecting penicillin susceptibility may not be reliable [
         <a href="#rid10">
          10
         </a>
         ]. Therefore, infective endocarditis (IE) caused by these organisms should be treated with regimens outlined for methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA) unless penicillin susceptibility can be confirmed  (
         <a class="graphic graphic_table graphicRef81429" href="/z/d/graphic/81429.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3864077705">
         <span class="h3">
          Methicillin susceptible
         </span>
        </p>
        <p class="headingAnchor" id="H2000924770">
         <span class="h4">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for NVE due to MSSA consists of a semisynthetic penicillin, such as
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         (
         <a class="graphic graphic_table graphicRef81429" href="/z/d/graphic/81429.html" rel="external">
          table 2
         </a>
         ).
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          Cefazolin
         </a>
         is an acceptable alternative agent [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          Cefazolin
         </a>
         may be used for patients with intracerebral septic emboli (in the absence of meningitis or brain abscess) since cefazolin is capable of reaching sites of endovascular infection. For patients with NVE in the setting of meningitis and/or brain abscess, treatment with
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         is preferred over cefazolin because of concerns about the ability of cefazolin to enter the CSF [
         <a href="#rid1">
          1
         </a>
         ]. Nevertheless, limited clinical series and pharmacokinetic considerations suggest that cefazolin at higher doses and/or continuous infusion may be a reasonable treatment for CNS infections [
         <a href="#rid12">
          12,13
         </a>
         ]. More clinical studies are needed to clarify this issue.
        </p>
        <p>
         Some experts caution against substituting
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         for
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         in the treatment of staphylococcal endocarditis because of concerns about the inoculum effect [
         <a href="#rid14">
          14
         </a>
         ]; this issue is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Methicillin-sensitive S. aureus'
         </a>
         .)
        </p>
        <p>
         However, to our knowledge, there are only two studies suggesting
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         was inferior to
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         for treatment of MSSA endocarditis; one was based on anecdotal observations of two patients with
         <em>
          S. aureus
         </em>
         endocarditis who relapsed after treatment or failed therapy [
         <a href="#rid15">
          15
         </a>
         ], and another reported relapse in a patient with a retained cardiac device [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Low-dose aminoglycosides should NOT be combined routinely with antistaphylococcal penicillins or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of native valve
         <em>
          S. aureus
         </em>
         endocarditis. The evidence for clinically significant benefit relative to potential harm is minimal [
         <a href="#rid17">
          17-19
         </a>
         ]. In a randomized trial including more than 230 patients with
         <em>
          S. aureus
         </em>
         bacteremia and endocarditis treated with either
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         monotherapy or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         combined with a antistaphylococcal penicillin (or vancomycin), those who received gentamicin experienced significantly more renal impairment than those who did not (22 versus 8 percent, respectively) [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         The duration of therapy for uncomplicated left-sided staphylococcal IE is six weeks; longer duration of therapy may be warranted in complicated IE [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3737653445">
         <span class="h4">
          Patients with penicillin allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NVE due to
         <em>
          S. aureus
         </em>
         who have a history of penicillin allergy can be treated with a first-generation cephalosporin such as
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         (2 g intravenously (IV) every eight hours), if there is no prior history of penicillin reaction that is typical of an immediate-type allergy [
         <a href="#rid1">
          1
         </a>
         ]. Alternately, if penicillin desensitization is undertaken and successful, treatment with an antistaphylococcal penicillin may be used. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
         Because of concerns about limited blood-brain barrier penetrability with
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , cefazolin is not considered first-line therapy for the treatment of patients with MSSA meningitis or brain abscess. If patients with MSSA IE and meningitis or brain abscess cannot tolerate
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         should be used. In situations where the patient does not tolerate vancomycin as well, cefazolin at higher doses and/or continuous infusion may be considered [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
         The American Heart Association (AHA) and the European Society for Cardiology (ESC) recommend
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         as an alternative in patients with penicillin allergy that is not anaphylactoid type [
         <a href="#rid1">
          1,2
         </a>
         ]; however, the British Society for Antimicrobial Chemotherapy (BSAC) recommends
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         therapy for all patients with penicillin allergy regardless of type [
         <a href="#rid3">
          3
         </a>
         ]. In addition, the BSAC recommends adding
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (300 to 600 mg orally every 12 hours) to vancomycin when treating methicillin-susceptible NVE in patients with penicillin allergy [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         are acceptable alternative agents for treatment of NVE due to MSSA in patients with immediate-type penicillin allergy (documented by formal allergy evaluation) [
         <a href="#rid1">
          1
         </a>
         ]. Vancomycin should not be used on the basis of convenience in patients without a true history of penicillin allergy, since clinical experience and in vitro studies have suggested that vancomycin is a less effective antistaphylococcal antibiotic than
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         . Issues related to use of vancomycin for treatment of MSSA infection are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Methicillin-sensitive S. aureus'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         is not an acceptable alternative agent for treatment of staphylococcal endocarditis, because relapse is common [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1341667378">
         <span class="h3">
          Methicillin resistant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of NVE due to methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) consists of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for six weeks  (
         <a class="graphic graphic_table graphicRef81429" href="/z/d/graphic/81429.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,2,20
         </a>
         ]. However, there have been a number of reports of vancomycin treatment failure in serious infections due to MRSA, even when isolates are proven to be susceptible using current microbiologic testing methods [
         <a href="#rid21">
          21-23
         </a>
         ]. Furthermore, there is some concern that infections due to
         <em>
          S. aureus
         </em>
         isolates with high minimum inhibitory concentration (MIC) yet still within the susceptible range may be associated with poorer outcomes (see
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         ). In clinical cases where patients are responding poorly to therapy or there is concern about vancomycin susceptibility, an alternative approach may be needed.
        </p>
        <p>
         For patients with MRSA IE who are unable to tolerate
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or for patients infected with an isolate with a vancomycin MIC &gt;1 (by broth microdilution, given high variability among other testing methods) [
         <a href="#rid24">
          24
         </a>
         ],
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (8 mg/kg/day) is an acceptable alternative agent [
         <a href="#rid1">
          1
         </a>
         ]. Daptomycin may be used for treatment of left- or right-sided IE, even if septic pulmonary emboli are present [
         <a href="#rid25">
          25,26
         </a>
         ]. Daptomycin should not be used in the setting of concomitant MRSA pneumonia [
         <a href="#rid1">
          1,20
         </a>
         ]. In one randomized trial including more than 240 patients with
         <em>
          S. aureus
         </em>
         bacteremia with or without endocarditis treated with daptomycin or standard therapy, the frequency of treatment success was comparable (44 versus 42 percent) [
         <a href="#rid18">
          18
         </a>
         ]. In a subsequent prospective cohort study including more than 170 patients with gram-positive left-sided IE treated with daptomycin or conventional therapy, the median time to clearance of bacteremia among patients treated with daptomycin was shorter (1 versus 5 days) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         We are in agreement with the AHA which recommends against addition of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of NVE due to MRSA
         <em>
         </em>
         [
         <a href="#rid1">
          1
         </a>
         ]; in contrast, the BSAC favors this approach
         <em>
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ]. In addition, we do not favor adjunctive use of rifampin for patients with staphylococcal NVE who undergo surgical management with prosthetic valve placement [
         <a href="#rid28">
          28
         </a>
         ]. The risk of rifampin-induced drug interactions and hepatic toxicity should be weighed carefully.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          Gentamicin
         </a>
         should NOT be combined with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of MRSA native valve IE [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Methicillin susceptible'
         </a>
         above.)
        </p>
        <p>
         Alternative agents for treatment of MRSA bacteremia are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         ). Thus far, there is insufficient evidence for routine use of agents such as teicoplanin,
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          ceftaroline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">
          telavancin
         </a>
         ,
         <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">
          dalbavancin
         </a>
         ,
         <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">
          oritavancin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         , or
         <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">
          tedizolid
         </a>
         for treatment of MRSA IE. Agents such as
         <a class="drug drug_general" data-topicid="9515" href="/z/d/drug information/9515.html" rel="external">
          quinupristin-dalfopristin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         , linezolid, tedizolid, or fluoroquinolones are generally not recommended for treatment of IE due to MRSA because of lack of sufficient evidence for treating IE and/or associated adverse effects.
        </p>
        <p class="headingAnchor" id="H764731136">
         <span class="h3">
          Coagulase-negative staphylococci
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment regimens for NVE due to coagulase-negative staphylococci are identical to those for coagulase-positive staphylococci. Most strains of coagulase-negative staphylococci are methicillin resistant. As a result, unless susceptibility to methicillin can be demonstrated conclusively, coagulase-negative staphylococci causing endocarditis should be assumed to be methicillin resistant and treated accordingly [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Methicillin resistant'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H722490282">
         <span class="h2">
          Streptococci
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Viridans streptococci and S. bovis/S. equinus complex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Members of the viridans group include
         <em>
          S. mitis
         </em>
         ,
         <em>
          S. mutans
         </em>
         ,
         <em>
          S. oralis
         </em>
         ,
         <em>
          S. sanguinis
         </em>
         ,
         <em>
          S. sobrinus
         </em>
         , and the
         <em>
          S. milleri
         </em>
         group (
         <em>
          S. anginosus
         </em>
         ,
         <em>
          S. constellatus
         </em>
         , and
         <em>
          S. intermedius
         </em>
         ).
        </p>
        <p>
         The nomenclature of the
         <em>
          S. bovis/S. equinus
         </em>
         complex is summarized in the table  (
         <a class="graphic graphic_table graphicRef89670" href="/z/d/graphic/89670.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3156.html" rel="external">
          "Infections due to Streptococcus bovis/Streptococcus equinus complex (SBSEC; formerly group D streptococci)"
         </a>
         .)
        </p>
        <p>
         The MIC breakpoints differ between the guidelines published by the AHA, British Society for Antimicrobial Chemotherapy (BSAC), and ESC; the MIC breakpoints are summarized in the tables  (
         <a class="graphic graphic_table graphicRef73007" href="/z/d/graphic/73007.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef53990" href="/z/d/graphic/53990.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1008787921">
         <span class="h4">
          Penicillin-susceptible strains
         </span>
         <span class="headingEndMark">
          —
         </span>
         MIC breakpoints and treatment regimens for endocarditis due to highly penicillin-susceptible streptococci are summarized in the table  (
         <a class="graphic graphic_table graphicRef73007" href="/z/d/graphic/73007.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         For treatment of patients with NVE due to highly penicillin-susceptible streptococci (defined by the AHA as MIC ≤0.12 mcg/mL), we are in agreement with the AHA and ESC which favor aqueous crystalline
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (12 to 18 million units daily for four weeks) or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g per day) for four weeks [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         In the setting of uncomplicated infection in the absence of pre-existing renal disease, patients who have a prompt response to therapy may be treated with a shortened (two week) duration of combination therapy with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         . In such cases, gentamicin may be given as a single daily dose (3 mg/kg per day; preferred in outpatients) or in two to three equally divided doses (adjusted to achieve a peak serum level of 3 to 4 mcg/mL; preferred in hospitalized patients when serum concentrations can be followed). In one randomized study including 61 patients with IE due to penicillin-susceptible streptococci treated with a four-week
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         regimen or a two-week combination of ceftriaxone plus gentamicin, cure rates were similar [
         <a href="#rid29">
          29
         </a>
         ]. In choosing between these regimens, one must weigh the risk of longer therapy with the potential risk of renal toxicity with gentamicin.
        </p>
        <p>
         Patients with penicillin allergy (in the absence of immediate-type hypersensitivity) may be treated with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         . Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for four weeks, or may be desensitized to penicillin and treated with a standard regimen. In general, treatment with penicillin is preferred over vancomycin; therefore, when feasible, we favor desensitization to penicillin over treatment with vancomycin. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3642907155">
         <span class="h4">
          Relatively penicillin-resistant strains
         </span>
         <span class="headingEndMark">
          —
         </span>
         MIC breakpoints and treatment regimens for endocarditis due to relatively penicillin-resistant streptococci are summarized in the table  (
         <a class="graphic graphic_table graphicRef53990" href="/z/d/graphic/53990.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         For treatment of patients with NVE due to relatively penicillin-resistant streptococci (defined by the AHA as MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL), we are in agreement with the AHA which recommends aqueous
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (24 million units daily, either continuously or in four to six equally divided doses) for a total of four weeks, in combination with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for the first two weeks.
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         monotherapy for four weeks is a reasonable alternative regimen (if the isolate is susceptible) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         monotherapy for four weeks. If feasible, we favor desensitization to penicillin over use of vancomycin [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1056662354">
         <span class="h4">
          Fully penicillin-resistant strains
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment of patients with NVE due to fully penicillin-resistant streptococci (defined by the AHA as MIC ≥0.5 mcg/mL) and streptococcal-like organisms (eg,
         <em>
          Abiotrophia defectiva
         </em>
         ,
         <em>
          Granulicatella
         </em>
         spp, and
         <em>
          Gemella
         </em>
         spp) with penicillin resistance, we are in agreement with the AHA which recommends treatment with regimens used for treatment of enterococcal endocarditis (eg,
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         18 to 30 million units IV per day plus
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         <sup>
         </sup>
         3 mg/kg IV per day for 4 to 6 weeks, or, for patients with penicillin allergy,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         30 mg/kg/day for 4 to 6 weeks)  (
         <a class="graphic graphic_table graphicRef50418" href="/z/d/graphic/50418.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. However, use of
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         is not an acceptable regimen for treatment of IE due to penicillin-resistant streptococci given insufficient clinical experience with this approach. (See
         <a class="local">
          'Enterococci'
         </a>
         below.)
        </p>
        <p>
         For isolates susceptible to
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         , treatment with ceftriaxone for four weeks in combination with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for the initial two weeks may be a reasonable alternative regimen [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3483646091">
         <span class="h4">
          Patients with penicillin allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         monotherapy; addition of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         is not needed [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Enterococci'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          Daptomycin
         </a>
         should not be used routinely as an alternative to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for the treatment of endocarditis caused by viridans streptococci; emergence of stable high-level resistance to daptomycin has been observed in at least 25 percent of the
         <em>
          Streptococcus mitis
         </em>
         group isolates (
         <em>
          S. mitis
         </em>
         ,
         <em>
          S. oralis
         </em>
         ,
         <em>
          S. sanguinis
         </em>
         ) with exposure to daptomycin in vitro and in experimental models. Resistance has also emerged in
         <em>
          Streptococcus parasanguinis
         </em>
         ,
         <em>
          Abiotrophia
         </em>
         , and
         <em>
          Granulicatella
         </em>
         species [
         <a href="#rid30">
          30-32
         </a>
         ]. In vitro and endocarditis model studies suggest that emergence of daptomycin resistance in streptococci can be prevented with daptomycin is combined with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Streptococcus pneumoniae
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumococcal endocarditis occurs in the context of pneumococcal pneumonia and may be complicated by concurrent meningitis [
         <a href="#rid35">
          35
         </a>
         ].
         <em>
          S. pneumoniae
         </em>
         strains relatively or fully resistant to penicillin are emerging; such strains may also be resistant to other beta-lactams and other antimicrobial agents.
        </p>
        <p class="headingAnchor" id="H3907628036">
         <span class="h4">
          Absence of meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of known or suspected concomitant meningitis, treatment of pneumococcal NVE consists of aqueous
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (24 million units per day IV, either continuously or in four to six divided doses); or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         for four weeks. Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for four weeks [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         dosing should be guided by MIC data [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with infection due to penicillin-susceptible
         <em>
          S. pneumoniae
         </em>
         (MIC ≤0.1 mcg/mL) or penicillin-intermediate
         <em>
          S. pneumoniae
         </em>
         (MIC &gt;0.1 to 1.0 mcg/mL), we use
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         2 g IV every 24 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with infection due to penicillin-resistant pneumococcal endocarditis (MIC ≥2 mcg/mL), we use
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         2 g IV every 12 hours.
        </p>
        <p>
        </p>
        <p>
         While in vitro beta-lactam resistance among pneumococci may be overcome by using higher doses of beta-lactams, clinical data on the efficacy of different doses for beta-lactams in this setting are limited [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3070983195">
         <span class="h4">
          Presence of meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of concomitant meningitis, in vitro susceptibility to
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         should be obtained. For patients with isolates susceptible to cefotaxime or ceftriaxone, treatment of pneumococcal NVE consists of cefotaxime (2 g IV every 4 to 6 hours) or ceftriaxone (2 g IV every 12 hours) for 4 weeks [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For patients with isolates resistant to
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (MIC ≥2.0 mcg/mL, which is the MIC definition for central nervous system isolates), addition of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 1
         </a>
         ) and
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (900 mg every 24 hours IV or by mouth in three divided doses) may be warranted.
        </p>
        <p>
         Issues related to extrameningeal infection with pneumococcal strains resistant to beta-lactam antibiotics are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3168.html" rel="external">
          "Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"
         </a>
         .)
        </p>
        <p>
         Pneumococcal endocarditis is usually fulminant and causes severe valve damage and embolic complications; valve replacement may be necessary [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">
          "Surgery for left-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3921350240">
         <span class="h3">
          Streptococcal groups A, B, C, F, and G
         </span>
         <span class="headingEndMark">
          —
         </span>
         Streptococcal groups A, B, C, F, and G are occasional causes of endocarditis [
         <a href="#rid35">
          35,38
         </a>
         ]. Regimens used to treat endocarditis due to viridans group streptococci are typically effective since most of these organisms are highly sensitive to penicillin.
        </p>
        <p>
         For treatment of IE due to
         <em>
          Streptococcus pyogenes
         </em>
         , we are in agreement with the AHA which recommends treatment with
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         (24 million units IV continuously or in 4 to 6 divided doses) for four to six weeks;
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (eg, IV every 12 hours) is a reasonable alternative and is easier to administer as an outpatient or in an intermediate care facility [
         <a href="#rid1">
          1
         </a>
         ].
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         may be used for patients intolerant of beta-lactam therapy.
        </p>
        <p>
         Some strains of groups B, C, F, and G streptococci are more resistant to penicillin than
         <em>
          S. pyogenes
         </em>
         . For this reason, depending on sensitivity results, we are in agreement with some experts who favor adding
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         to a penicillin or cephalosporin for the first two weeks of a four- to six-week course of therapy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Enterococci
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of enterococcal endocarditis are caused by
         <em>
          E. faecalis
         </em>
         strains [
         <a href="#rid39">
          39
         </a>
         ].
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         resistance is observed most commonly among
         <em>
          Enterococcus faecium
         </em>
         strains, which are a less frequent cause of endocarditis.
        </p>
        <p>
         Enterococci have a narrower spectrum of susceptibility than streptococcal species. In particular, members of the genus
         <em>
          Enterococcus
         </em>
         are all resistant to low concentrations of penicillin. They are also relatively resistant to expanded-spectrum penicillins, resistant to cephalosporins, and typically resistant to aminoglycosides at concentrations achieved with standard dosing regimens. However, many strains of enterococci are killed both in vitro and in vivo if penicillin,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is given in synergistic combination with an aminoglycoside such as
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         . Issues related to enterococcal resistance are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/470.html" rel="external">
          "Mechanisms of antibiotic resistance in enterococci"
         </a>
         .)
        </p>
        <p>
         Enterococci should be tested routinely for in vitro susceptibility to penicillin and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and for high-level resistance to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         (&gt;500 mcg/mL) to predict synergistic interactions [
         <a href="#rid1">
          1
         </a>
         ]. For strains that are resistant to beta-lactams or vancomycin, in vitro susceptibility to
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         should be obtained.
        </p>
        <p>
         General principles related to treatment of enterococcal infections are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">
          "Treatment of enterococcal infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Susceptible strains
         </span>
        </p>
        <p class="headingAnchor" id="H185415087">
         <span class="h4">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment regimens for NVE due to enterococcal strains susceptible to penicillin and
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         are summarized in the table  (
         <a class="graphic graphic_table graphicRef50418" href="/z/d/graphic/50418.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. Regimens include a beta-lactam combination regimen (
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         plus
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         for six weeks, for IE due to
         <em>
          E. faecalis
         </em>
         ) or an aminoglycoside combination regimen (penicillin or ampicillin plus gentamicin for four to six weeks; the duration of gentamicin may be shortened to two weeks in the setting of nephrotoxicity, as discussed below). Most strains of
         <em>
          E. faecium
         </em>
         are not susceptible to ampicillin; in the setting of IE due to
         <em>
          E. faecium
         </em>
         , the combination beta-lactam regimen should not be used.
        </p>
        <p>
         For patients with NVE due to enterococcal strains susceptible to penicillin and
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         , we favor treatment with a beta-lactam combination regimen. This approach may be better tolerated and associated with fewer side effects than regimens containing an aminoglycoside, particularly in older patients and/or in patients with renal insufficiency [
         <a href="#rid40">
          40-43
         </a>
         ]. In an observational study including more than 240 patients (mostly in Spain) with
         <em>
          E. faecalis
         </em>
         IE who were treated with either
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         or ampicillin and gentamicin (AG), rates of mortality, treatment failure, and relapse were comparable between the groups; renal failure occurred more frequently among those treated with AG [
         <a href="#rid43">
          43
         </a>
         ]. Similarly, in a retrospective study including 279 patients in France with
         <em>
          E. faecalis
         </em>
         IE, the relapse rate was comparable among patients treated with ampicillin and ceftriaxone or AG (13 to 14 percent) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         For patients treated with an aminoglycoside combination regimen, some experts prefer penicillin over
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         because of the possibility of increased allergic reaction to ampicillin. Patients with duration of symptoms &lt;3 months may be treated successfully with four weeks antimicrobial therapy [
         <a href="#rid45">
          45
         </a>
         ]; six weeks of therapy is preferred for patients with duration of symptoms &gt;3 months and patients with relapsed infection.
        </p>
        <p>
         Longer duration of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         treatment has been associated with increased likelihood for decline in renal function. In one nonrandomized study including more than 80 patients with enterococcal IE with absence of high-level aminoglycoside resistance and duration of symptoms &lt;3 months, two weeks of gentamicin (in combination with a cell wall-active agent for four to six weeks) was adequate [
         <a href="#rid46">
          46
         </a>
         ]. Pending further data, four to six weeks of gentamicin should be administered for patients with no concern for aminoglycoside toxicity.
        </p>
        <p class="headingAnchor" id="H4151144394">
         <span class="h4">
          Patients with penicillin allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with immediate-type hypersensitivity reaction to beta-lactams may be treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for six weeks  (
         <a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">
          table 7
         </a>
         ), or may be desensitized to penicillin and treated with a standard regimen. In general, treatment with penicillin is preferred over vancomycin; therefore, when feasible we favor desensitization to penicillin over treatment with vancomycin. For patients treated with vancomycin, a six-week duration of therapy should be administered (rather than four weeks), because vancomycin has diminished activity against enterococci compared with penicillin [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Gentamicin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment regimens for NVE due to enterococcal strains susceptible to penicillin,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         but resistant to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         are summarized in the table  (
         <a class="graphic graphic_table graphicRef104581" href="/z/d/graphic/104581.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         For patients with NVE due to enterococcal strains that are susceptible to penicillin,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         but resistant to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         , we are in agreement with the AHA which recommends combination therapy with a beta-lactam combination regimen (
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         plus
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         for six weeks)  (
         <a class="graphic graphic_table graphicRef104581" href="/z/d/graphic/104581.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. An aminoglycoside combination regimen (penicillin or ampicillin plus streptomycin, both for four to six weeks) is an alternative provided that the patient does not have pre-existing renal dysfunction or cranial nerve VIII dysfunction.
        </p>
        <p>
         It is uncertain whether a shortened duration of
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         is adequate; thus far, data supporting shorter duration of aminoglycoside therapy are based on studies with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         . (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
         Additional considerations regarding management of patients with immediate-type hypersensitivity reaction to beta-lactams are discussed above. (See
         <a class="local">
          'Patients with penicillin allergy'
         </a>
         above.)
        </p>
        <p>
         Some gentamicin-resistant strains lack
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         resistance, and vice versa. For treatment of IE due to enterococci resistant to both streptomycin and
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         , aminoglycosides are not beneficial. (See
         <a class="local">
          'Resistance to penicillin, aminoglycosides, and vancomycin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Penicillin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment regimens for NVE due to enterococcal strains with penicillin resistance are summarized in the table  (
         <a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         For patients with NVE due to enterococcal strains with intrinsic high-level penicillin resistance (MIC ≥16 mcg/mL), we are in agreement with the AHA which recommends combination therapy with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for six weeks  (
         <a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Resistance to penicillin, aminoglycosides, and vancomycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment regimens for NVE due to enterococcal strains with resistance to penicillin, aminoglycosides, and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         are summarized in the table  (
         <a class="graphic graphic_table graphicRef66444" href="/z/d/graphic/66444.html" rel="external">
          table 9
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The optimal approach to treatment of endocarditis due to enterococci with high-level aminoglycoside and/or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         resistance is uncertain. We favor treatment with
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (in combination with an additional agent such as
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         or
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          ceftaroline
         </a>
         ) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Data on management of vancomycin-resistant enterococcal IE are limited; the approach is guided by limited data in patients with bacteremia. In one retrospective cohort study including more than 600 patients with bloodstream infections due to vancomycin-resistant enterococci treated with
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         , treatment with linezolid was associated with higher risk of treatment failure (risk ratio 1.15, 95% CI 1.02-1.30) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Issues related to treatment of enterococcal bacteremia are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">
          "Treatment of enterococcal infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          HACEK organisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of fastidious gram-negative bacilli are grouped by the acronym "HACEK" – these include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           H
          </em>
         </strong>
         <em>
          aemophilus aphrophilus
         </em>
         (subsequently called
         <em>
          Aggregatibacter aphrophilus
         </em>
         and
         <em>
          Aggregatibacter paraphrophilus
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           A
          </em>
         </strong>
         <em>
          ctinobacillus actinomycetemcomitans
         </em>
         (subsequently called
         <em>
          Aggregatibacter actinomycetemcomitans
         </em>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           C
          </em>
         </strong>
         <em>
          ardiobacterium hominis
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           E
          </em>
         </strong>
         <em>
          ikenella corrodens
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           K
          </em>
         </strong>
         <em>
          ingella kingae
         </em>
        </p>
        <p>
        </p>
        <p>
         HACEK organisms are isolated readily when incubated for five days with automated blood culture systems. Longer incubation periods (&gt;6 days) may be required to detect growth if traditional (non-automated) blood culture systems are used.
        </p>
        <p>
         HACEK organisms are considered
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         resistant. Unless growth in vitro is adequate to obtain susceptibility testing results, penicillin and ampicillin should not be used for treatment of IE due to these organisms [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Virtually all HACEK organisms are highly susceptible to third-generation cephalosporins such as
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         , even strains that produce beta-lactamase.
        </p>
        <p>
         Treatment regimens for NVE due to HACEK organisms are summarized in the table  (
         <a class="graphic graphic_table graphicRef70411" href="/z/d/graphic/70411.html" rel="external">
          table 10
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         We are in agreement with the AHA which recommends treatment with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         (if in vitro testing is feasible and the organism is susceptible), or
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         for four weeks [
         <a href="#rid1">
          1
         </a>
         ].
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          Gentamicin
         </a>
         is generally not recommended because of risk for nephrotoxicity.
        </p>
        <p class="headingAnchor" id="H933452042">
         <span class="h2">
          Other gram-negative organisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         NVE due to other gram-negative bacilli (such as
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Pseudomonas
         </em>
         ,
         <em>
          Klebsiella
         </em>
         , or
         <em>
          Serratia
         </em>
         ) is extremely rare. The most common predisposing factor is an implanted endovascular device, and most cases occur in the setting of recent health care contact [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         The choice of antimicrobial therapy depends on the antimicrobial susceptibility of the causative organism.
        </p>
        <p>
         Combination antimicrobial therapy with a beta-lactam (penicillins, cephalosporins, or carbapenems) and either an aminoglycoside or fluoroquinolone for six weeks is reasonable [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Such patients may also warrant cardiac surgery, particularly in the setting of left-sided infection due to
         <em>
          Pseudomonas
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">
          "Surgery for left-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H407500424">
         <span class="h2">
          Fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of fungal endocarditis consists of antifungal therapy and valve replacement.
        </p>
        <p>
         Issues related to
         <em>
          Candida
         </em>
         endocarditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">
          "Candida endocarditis and suppurative thrombophlebitis"
         </a>
         .)
        </p>
        <p>
         Issues related to endocarditis caused by
         <em>
          Aspergillus
         </em>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Antifungal therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Duration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Role of surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          CULTURE-NEGATIVE ENDOCARDITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Culture-negative infective endocarditis is defined as endocarditis without etiology following inoculation of three blood samples in a standard blood culture system (eg, negative cultures after seven days) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Cultures are negative in IE for three major reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of antimicrobial agents prior to blood culture incubation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate microbiologic techniques
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection with fastidious bacteria or nonbacterial pathogens
        </p>
        <p>
        </p>
        <p>
         The most common causes of culture-negative IE are fastidious organisms (eg, zoonotic agents and fungi) and
         <em>
          Streptococcus
         </em>
         spp in patients who have received previous antibiotic treatment.
        </p>
        <p>
         <em>
          Coxiella burnetii
         </em>
         and
         <em>
          Bartonella
         </em>
         spp are relatively common agents of culture-negative endocarditis; the frequency varies in different geographic locations.
        </p>
        <p>
         Empiric treatment of patients with culture-negative NVE should cover both gram-positive and gram-negative organisms and should be selected in consultation with an infectious disease specialist. The American Heart Association suggests the following approach [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with acute clinical presentation (ie, symptomatic for days), antimicrobial therapy for coverage of infection due to
         <em>
          S. aureus
         </em>
         , beta-hemolytic streptococci, and aerobic gram-negative bacilli is reasonable. Empiric coverage could include
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         as an initial regimen [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a subacute clinical presentation (ie, symptomatic for weeks), antimicrobial therapy for coverage of infection due to
         <em>
          S. aureus
         </em>
         , viridans group streptococci, HACEK organisms, and enterococci is reasonable. Empiric coverage could include
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         as an initial regimen [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The above approach to empiric treatment can be modified depending on individual patient circumstances, including whether the patient received antimicrobial therapy prior to blood cultures, the type and duration of prior antimicrobial therapy, epidemiologic risk factors, the suspected site of primary infection, risk of toxicity, and allergy history. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients for whom gram-positive cocci or HACEK organisms are the most likely cause of endocarditis, we sometimes use a combination of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         or vancomycin plus
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients receiving dialysis, a regimen consisting of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         alone may be reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients for whom there is a reasonable possibility of infection with an organism such as
         <em>
          C. burnetii
         </em>
         or
         <em>
          Brucella,
         </em>
         empiric therapy active against these pathogens is reasonable, pending test results. (See
         <a class="medical medical_review" href="/z/d/html/121314.html" rel="external">
          "Brucellosis: Treatment and prevention", section on 'Endocarditis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Subsequent therapy should be directed to the specific microorganism if diagnostic tests such as polymerase chain reaction or serology identify the etiologic agent.
        </p>
        <p>
         For patients with IE and negative blood cultures who undergo valve replacement, the approach to antibiotic therapy may be guided by valve culture data. (See
         <a class="medical medical_review" href="/z/d/html/2148.html" rel="external">
          "Surgery for left-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3358364708">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112042.html" rel="external">
          "Society guideline links: Treatment and prevention of infective endocarditis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/121914.html" rel="external">
          "Society guideline links: Outpatient parenteral antimicrobial therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H349231560">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17037.html" rel="external">
          "Patient education: Endocarditis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H286258840">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General considerations
         </strong>
         − Treatment of endocarditis requires bactericidal antimicrobial therapy, which should be dosed to optimize sustained bactericidal serum concentrations throughout as much of the dosing interval as possible. In vitro determination of the minimum inhibitory concentration should be performed routinely. (See
         <a class="local">
          'General considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consultation
         </strong>
         − Early consultation with a cardiac surgeon should be obtained for cases in which complications are observed or expected (such as in the presence of moderate to severe heart failure, heart block, or systemic emboli). In addition, consultation with specialists in infectious diseases and/or cardiology may be important. (See
         <a class="local">
          'General considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Whom to treat
         </strong>
         − For patients with hemodynamic instability and clinical presentation suggestive of acute endocarditis (fever and new murmur, particularly in the setting of relevant cardiac risk factors or other predisposing conditions), we suggest administration of empiric antibiotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who present without acute symptoms, empiric therapy is not always necessary; initiation of treatment can await blood culture results.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Collecting blood cultures prior to antibiotics
         </strong>
         − Empiric therapy may be administered after at least two (preferably three) sets of blood cultures have been obtained from separate venipunctures and ideally spaced over 30 to 60 minutes. (See
         <a class="local">
          'Empiric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotic selection
         </strong>
         − In general, empiric therapy should cover staphylococci (methicillin susceptible and resistant), streptococci, and enterococci.
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         is an appropriate choice for initial therapy in most patients. (See
         <a class="local">
          'Empiric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tailoring treatment
         </strong>
         − The optimal antibiotic regimen depends upon the causative organism and in vitro susceptibility results. The approach is summarized in the tables and is discussed in the sections above:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Staphylococci  (
         <a class="graphic graphic_table graphicRef81429" href="/z/d/graphic/81429.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Staphylococci'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Streptococci:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Viridans streptococci and
         <em>
          S. bovis
         </em>
         /
         <em>
          S. equinus
         </em>
         complex  (
         <a class="graphic graphic_table graphicRef89670" href="/z/d/graphic/89670.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef73007" href="/z/d/graphic/73007.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef53990" href="/z/d/graphic/53990.html" rel="external">
          table 5
         </a>
         ) (see
         <a class="local">
          'Viridans streptococci and S. bovis/S. equinus complex'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          S. pneumoniae
         </em>
         (see
         <a class="local">
          'Streptococcus pneumoniae'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Streptococcal groups A, B, C, F, and G (see
         <a class="local">
          'Streptococcal groups A, B, C, F, and G'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enterococci  (
         <a class="graphic graphic_table graphicRef50418" href="/z/d/graphic/50418.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef64258" href="/z/d/graphic/64258.html" rel="external">
          table 7
         </a>
         and
         <a class="graphic graphic_table graphicRef104581" href="/z/d/graphic/104581.html" rel="external">
          table 8
         </a>
         and
         <a class="graphic graphic_table graphicRef66444" href="/z/d/graphic/66444.html" rel="external">
          table 9
         </a>
         ) (see
         <a class="local">
          'Enterococci'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HACEK organisms  (
         <a class="graphic graphic_table graphicRef70411" href="/z/d/graphic/70411.html" rel="external">
          table 10
         </a>
         ) (see
         <a class="local">
          'HACEK organisms'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other gram-negative organisms (see
         <a class="local">
          'Other gram-negative organisms'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culture-negative endocarditis (see
         <a class="local">
          'Culture-negative endocarditis'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration
         </strong>
         (see
         <a class="local">
          'Duration of therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The suggested duration of therapy in patients with NVE depends on the pathogen and site of valvular infection. In general, the suggested duration of therapy in patients with NVE ranges up to six weeks (with the exception of NVE due to highly resistant enterococcus, for which the duration is at least six weeks).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some data suggest that a shortened duration of intravenous therapy may be sufficient in some cases; however, thus far, the weight of this evidence has been insufficient to change practice. A full course of therapy is particularly important for patients with virulent or relatively resistant pathogens, secondary cardiac or extracardiac complications, and in the setting of prolonged infection prior to diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         − Patients with endocarditis require careful regular clinical follow-up that includes serial physical examinations and obtaining follow-up blood cultures to document clearance of bacteremia. (See
         <a class="local">
          'Follow up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H109166495">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Daniel J Sexton, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019; 380:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bundgaard H, Ihlemann N, Gill SU, et al. Long-Term Outcomes of Partial Oral Treatment of Endocarditis. N Engl J Med 2019; 380:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durack DT, Beeson PB. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol 1972; 53:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karchmer AW, Moellering RC Jr, Maki DG, Swartz MN. Single-antibiotic therapy for streptococcal endocarditis. JAMA 1979; 241:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. N Engl J Med 2022; 386:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Feghaly RE, Stamm JE, Fritz SA, Burnham CA. Presence of the bla(Z) beta-lactamase gene in isolates of Staphylococcus aureus that appear penicillin susceptible by conventional phenotypic methods. Diagn Microbiol Infect Dis 2012; 74:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019; 25:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antosz K, Battle S, Chang J, et al. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation. Pharmacotherapy 2023; 43:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCreary EK, Johnson MD, Jones TM, et al. Antibiotic Myths for the Infectious Diseases Clinician. Clin Infect Dis 2023; 77:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994; 121:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 1977; 237:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003; 37:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sander A, Beiderlinden M, Schmid EN, Peters J. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002; 28:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 Suppl 1:S31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother 2013; 68:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008; 62:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carugati M, Bayer AS, Miró JM, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother 2013; 57:6213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrestha NK, Shah SY, Wang H, et al. Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study. Ann Thorac Surg 2016; 101:2243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pericàs JM, Nathavitharana R, Garcia-de-la-Mària C, et al. Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-de-la-Mària C, Pericas JM, Del Río A, et al. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin. Antimicrob Agents Chemother 2013; 57:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cañas MA, Téllez A, García de la Mària C, et al. Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis. Antimicrob Agents Chemother 2021; 65:e0252220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-de-la-Maria C, Xiong YQ, Pericas JM, et al. Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebriaei R, Rice SA, Stamper KC, et al. Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronin SI, Mukherjee SK, West JC, Cooney EL. Review of pneumococcal endocarditis in adults in the penicillin era. Clin Infect Dis 1998; 26:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez E, Miró JM, Almirante B, et al. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis 2002; 35:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefort A, Mainardi JL, Selton-Suty C, et al. Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group. Medicine (Baltimore) 2000; 79:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM. Infective endocarditis caused by beta-hemolytic streptococci. The Infectious Diseases Society of America's Emerging Infections Network. Clin Infect Dis 1998; 26:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014; 20:O1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beganovic M, Luther MK, Rice LB, et al. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clin Infect Dis 2018; 67:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Rafei A, DeSimone DC, Narichania AD, et al. Comparison of Dual β-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis. J Infect 2018; 77:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danneels P, Hamel JF, Picard L, et al. Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse. Clin Infect Dis 2023; 76:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson WR, Wilkowske CJ, Wright AJ, et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013; 127:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pericàs JM, García-de-la-Mària C, Brunet M, et al. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis. J Antimicrob Chemother 2017; 72:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clin Infect Dis 2015; 61:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med 2007; 147:829.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2152 Version 80.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320109" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22086858" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30152252" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30883059" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Long-Term Outcomes of Partial Oral Treatment of Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4111329" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/107335" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Single-antibiotic therapy for streptococcal endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139280" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959917" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Presence of the bla(Z) beta-lactamase gene in isolates of Staphylococcus aureus that appear penicillin susceptible by conventional phenotypic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928559" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36521869" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37310038" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibiotic Myths for the Infectious Diseases Clinician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7978701" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/576284" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Unsuccessful treatment of staphylococcal endocarditis with cefazolin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557964" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6751182" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16914701" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207079" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12185441" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11137406" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15227615" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32191793" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23190763" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Daptomycin for the treatment of infective endocarditis: results from a European registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18782781" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24080644" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26872729" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9868662" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31182540" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478959" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34252304" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28264848" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30962347" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9455526" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Review of pneumococcal endocarditis in adults in the penicillin era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12087518" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11039081" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9455511" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Infective endocarditis caused by beta-hemolytic streptococci. The Infectious Diseases Society of America's Emerging Infections Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057570" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25040215" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29390132" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29969596" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparison of Dualβ-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392394" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36124844" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6426359" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23543002" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28204495" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26063715" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18087053" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Non-HACEK gram-negative bacillus endocarditis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
